Adial Pharmaceuticals IPO Research Information

Adial Pharmaceuticals IPO Advisory

Share this IPO Profile:

Smart Search

For IPO Boutique's "scale of 1 to 5" BUY rating on Adial Pharmaceuticals, and our comprehensive analysis, click "Buy Market Research".

Company	Symbol	Price Range	Issue Price	Open	Shares	Trade Date
Adial Pharmaceuticals	ADIL - NASDAQ	$5.00-$5.00	$5.00	$4.00	1.5 million	7/27/2018
Underwriter(s): Joseph Gunnar & Co.
Co-Manager(s): Dawson James Securities
Industry: Health Care
Filing(s): Filed 2018-04-16 1st Filed 2017-09-07 Terms Added 2017-09-25 Underwriters Added 2017-10-25 Underwriter's Changed 2018-06-11

Adial Pharmaceuticals Quote & Chart - Click for current quote - ADIL

About Adial Pharmaceuticals (adapted from Adial Pharmaceuticals prospectus):
They are a clinical-stage biopharmaceutical company focused on the development of a therapeutic agent for the treatment of alcohol use disorder using their lead investigational new drug product, AD04, a selective serotonin-3 antagonist.

This description is adapted from prospectus. This description is not intended to be a recommendation to buy stock from this company. To see the company's full description, view their prospectus.

IPO Boutique aggregates information on public companies and private companies, such as "ADIL" IPO, which is intended to educate our readers and help them evaluate potential investment opportunities and market conditions. We endeavor to research the financial industry and obtain independent verification of factual statements before presenting them to our users. Be informed.